Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Steven G. DuBois, MD, MS
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital for Sick Children
Toronto, Ontario, Canada
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- C.S. Mott Children'S Hospital
Ann Arbor, Michigan, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
- Seattle Children'S Hospital
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Sept 2019
- Primary completion
- 16 Mar 2024
- Completion
- 1 Oct 2024
- Last update posted
- 2 Oct 2024
- Registered enrollment
- 41
- Registry id
- NCT03936465
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.